Vertex Pharmaceuticals has secured two simultaneous US Food and Drug Administration (FDA) approvals for cystic fibrosis (CF ... application for VX-522, a product of the collaboration that is ...

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis ... s pipeline includes VX-522, a CFTR mRNA ...

Vertex built its business treating the underlying genetic cause of cystic fibrosis (CF), a rare ... One is from a phase 1/2 study evaluating VX-522, a messenger RNA therapy that could treat ...

VX-522: The multiple ascending dose (MAD ... Vertex increased its estimates for the number of people with cystic fibrosis in the U.S., Europe, Australia, and Canada from approximately 92,000 ...

VX-522: The multiple ascending dose (MAD ... Epidemiology and market opportunity update: Vertex increased its estimates for the number of people with cystic fibrosis in the U.S., Europe, Australia, ...